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Abstract We elucidated the intron-exon boundaries of the 15
coding exons of the human cystathionine L-synthase (CBS) gene
in order to establish an improved method based on PCR and
direct sequencing for detection of CBS mutations. Using this
method we identified the pathogenic mutations in two Danish
siblings with CBS deficiency. Patients were compound hetero-
zygotes: we detected the 833TCC mutation and a novel 22 bp
deletion of exon 4 (493^514del) that introduces a frameshift and
a stop codon immediately after the deletion. The deletion resulted
in no detectable mRNA from this allele, as assessed by
sequencing of cDNA. The established method represents an
improvement of the existing method based on sequencing of
cDNA because it permits the detection of mutations within the
entire coding region of the CBS gene from a peripheral blood
sample, including splice mutations and mutations resulting in the
lack or a reduced amount of transcript.
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1. Introduction
Homocystinuria due to cystathionine L-synthase de¢ciency
(CBS; EC 4.2.1.22) is the most common inborn error of sul-
phur amino acid metabolism. It is an autosomal recessive
disease with an estimated incidence of approximately
1:200 000. The clinical manifestations include premature athe-
rosclerosis and early thromboembolism, mental retardation,
psychotic behaviour and seizures, optic lens dislocation, os-
teoporosis and skeletal abnormalities. Vascular complications
comprise the major cause of death [1].
The human CBS gene maps to chromosome 21q22.3 [2] and
encodes a protein of 551 amino acids [3]. The CBS enzyme is
a cytosolic homotetramer of 63 kDa subunits [4] that catalyses
the condensation of homocysteine with serine, forming cysta-
thionine. The enzyme requires pyridoxal 5P-phosphate (PLP,
the active form of vitamin B6) as co-factor, and patients are
classi¢ed as pyridoxine-responsive or non-responsive accord-
ing to the homocysteine lowering e¡ect of pyridoxine treat-
ment. Usually, pyridoxine-responsive patients tend to have a
milder clinical phenotype than do pyridoxine non-responsive
patients. However, the severity of the disease varies strongly
and can vary from normal to severe in patients with no meas-
urable CBS activity although many of these patients are pyr-
idoxine-responsive. Furthermore, variation in phenotypes be-
tween patients with the same genotype is observed [5],
demonstrating the lack of a well-de¢ned correlation between
genotype and phenotype in CBS de¢ciency.
The cDNA sequence of the CBS gene was published in 1993
[3]. To date, more than 80 mutations have been detected in
the CBS gene in CBS-de¢cient patients (Kraus et al., unpub-
lished), the majority being missense mutations. Using di¡erent
in vitro expression systems, the pathogenic property has been
determined for some of the mutations [5,6]. So far, analyses of
these defects have mainly been performed using ¢broblast-
derived cDNA. No results of a complete screening of the
CBS gene on genomic DNA have as yet been published,
although such an analysis would facilitate detection of genetic
variations such as splice mutations and mutations leading to a
null allele.
We therefore established a screening method based on ge-
nomic DNA for detection of mutations in the CBS gene. This
was made possible by the elucidation of the intron-exon boun-
daries of the 15 coding exons. Knowledge of those boundaries
enabled the design of speci¢c intronic primers for ampli¢ca-
tion of all coding exons. These PCR products were subse-
quently sequenced directly. We here report the detection of
a novel deletion and a previously identi¢ed missense mutation
in two Danish siblings with partly pyridoxine-responsive ho-
mocystinuria due to CBS de¢ciency. Using the conventional
method based on sequencing of cDNA only the missense mu-
tation would have been identi¢ed.
2. Materials and methods
2.1. Patients
Patients 1 and 2 were two Danish siblings with severe hyperhomo-
cysteinemia (Fig. 1). No diagnosis of CBS de¢ciency had been made
prior to referral. Patient 1 is a 34-year-old male who su¡ered a spon-
taneous deep venous thrombosis (DVT) at the age of 19, and recur-
rence at the age of 28 years. Since the ¢rst thrombotic episode he has
been treated for symptoms of psychosis. At present, treatment consists
of clozapine. Furthermore, specialist eye investigation revealed stra-
bismus, myopia and astigmatism, but no signs of dislocated optic
lenses. There is no mental retardation or radiographic signs of osteo-
porosis. Patient 2 is a 22-year-old female who developed a spontane-
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ous incident of DVT, complicated by pulmonary embolism, at the age
of 21 years, using no hormonal contraceptives. She has never pre-
sented with mental retardation or other sequelae of CBS de¢ciency,
and her bone structure as assessed by X-ray is normal.
2.2. Determination of total homocysteine in plasma
Total homocysteine in plasma was measured by gas chromatogra-
phy-mass spectrometry, using stable isotope dilution. Samples were
collected in tubes containing heparin as an anticoagulant and with
sodium £uoride added to a ¢nal concentration of 4 g/l [7]. Plasma
was separated by centrifugation within 2 h.
2.3. Isolation of RNA, cDNA synthesis and DNA isolation
RNA was isolated from phytohaemagglutinin-stimulated (72 h)
lymphocytes using a modi¢ed phenol-chloroform-based method, the
RNAzol B method (WAK-Chemie Medical GmbH, Bad Homburg
v.d.H., Germany). cDNA synthesis was performed using an
oligodT18 primer and the First Strand cDNA synthesis kit (Pharma-
cia, Uppsala, Sweden). For analysis of genomic DNA, we isolated
DNA from 300 Wl EDTA-stabilised blood using the Puregene DNA
isolation kit (Gentra Systems, Inc., Minneapolis, MN, USA).
2.4. PCR ampli¢cation of CBS genomic DNA
For elucidation of the intron-exon boundaries, PCR was carried
out in a volume of 50 Wl containing V200 ng of isolated DNA,
7.5 pmol of each primer, 120 WM of each dNTP, 6% DMSO, 2.5 units
Taq and Pwo polymerase (Expand long template PCR system, Boehr-
inger Mannheim) in the bu¡er supplied with the enzyme. Ampli¢ca-
tions were performed in an OmniGene automatic temperature cycler
(Hybaid, Middlesex, UK) using the following conditions: 2 min at
94‡C, 1 min at 65‡C and 2 min 30 s at 68‡C for one cycle followed by
35 cycles of 94‡C for 20 s, 65‡C for 30 s and 68‡C for 2 min 30 s,
using the tube control mode of the thermal cycler.
The exon-speci¢c PCR analyses were carried out in a volume of 50
Wl containing V200 ng of isolated DNA, 7.5 pmol of each primer
(Table 3), 120 WM of each dNTP, 6% DMSO, 1 unit Taq polymerase
(Amplitaq Gold, Perkin Elmer) in the bu¡er supplied with the en-
zyme. Ampli¢cations were performed in an OmniGene automatic tem-
perature cycler using the following conditions: 10 min at 94‡C, 1 min
at the appropriate annealing temperature (Table 3) and 45 s at 72‡C
for one cycle followed by 35 cycles of 94‡C for 30 s, annealing for 45 s
and 72‡C for 45 s, using the tube control mode of the thermal cycler.
2.5. Sequencing of PCR products
We used the prism AmpliTaq FS DNA polymerase dye primer
sequencing kit (321M13 and M13 reverse) (Perkin Elmer Cetus, Nor-
walk, CA) for sequencing of the PCR products. PCR products were
subjected to automated cycle sequencing using a Catalyst 800 Molec-
ular Biology LabStation (Perkin Elmer Cetus). The following cycle
conditions were used: 15 cycles of 95‡C for 20 s, 55‡C for 50 s and
68‡C for 60 s followed by 15 cycles of 95‡C for 25 s and 68‡C for 60 s.
Sequencing products were run in a 4.75% polyacrylamide gel using an
ABI Prism 377 DNA Sequencer (Applied Biosystems).
2.6. CBS enzyme assay
Skin biopsy ¢broblast cultures were established from both patients
for enzyme activity measurements according to [8]. CBS activity was
measured in patient ¢broblasts as described elsewhere [9]. Assays were
performed with and without addition of 1 mM PLP to the incubation
mixture, and after stimulation with 100 WM S-adenosylmethionine
(AdoMet).
3. Results
3.1. Elucidation of the intron-exon boundaries of the CBS gene
Using primers speci¢c to the human CBS cDNA sequence,
we ampli¢ed several PCR products containing intronic se-
quences between contiguous exons, using M13 tailed primers.
These fragments were sequenced directly in both directions
using M13 sense or antisense sequencing primers, and the
intron-exon boundaries of the 15 coding exons were deter-
mined (Table 1). At least 30 bp of each, or the entire intron
sequence is listed in Table 2.
3.2. Ampli¢cation and sequencing of genomic DNA
Exon-speci¢c primers were designed from the intron se-
quences for ampli¢cation of the 15 CBS exons (Table 3). By
designing intron-speci¢c primers, ampli¢cation of the intron-
exon boundaries was made possible. This enables the detec-
tion of splice mutations in the subsequent sequencing analysis.
The addition of an M13 tail, sense and antisense, respectively
(Table 3) to the 5P end of each primer, allows sequencing of
all 15 exons using the same sequencing primers. Following
PCR ampli¢cation of exons 1^15 from genomic DNA, the
PCR products were sequenced directly using a semi-auto-
mated sequencing procedure and M13 dye primers.
3.3. Detection of CBS mutations from patients
The established method was used for detection of mutations
in the CBS gene in patients 1 and 2 that were referred for
thrombophilia investigation at our department. Both had se-
vere hyperhomocysteinemia (s 100 Wmol total homocysteine/l
plasma) [11]. Initially, the search for CBS mutations was per-
formed by the conventional method involving sequencing of
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Table 1
Intron-exon boundaries of the human cystathionine L-synthase gene
Exon/Intron
No.
5P Exon sequence Exon size
(bp)
3P Exon sequencea 5P Intron splice site
(donor)
Intron sizeb 3P Intron splice site
(acceptor)
1 ATGCCTTCTG 209c ACACTGCCCC (209) gtaagt 3367 tttcag
2 GGCAAAATCT 107 TGTGAGCTCT (316) gtgagt 2132 tcccag
3 TGGCCAAGTG 135 GGGAACACCG (451) gtgggt 548 cctcag
4 GGATCGGGCT 80 CTCCGAGAAG (531) gtgggt 94 ctgcag
5 GTGGACGTGC 135 CCTAGACCAG (666) gtgagg 114 atgcag
6 TACCGCAACG 70 CAGTGTGATG (736) gtgcgt 1212 caccag
7 GGAAGCTGGA 92 TGGATGCAGG (828) gtgagt 821 ctgcag
8 ATCATTGGGG 126 GGACAGGACG (954) gtaggt 556 gctcag
9 GTGGTGGACA 85 CTGCTGTGCG (1039) gtgagt 1761 ctgcag
10 GTGGCAGTGC 106 GGAACTACAT (1145) gtaaga 1132 ccgcag
11 GACCAAGTTC 78 AGAAGCCCTG (1223) gtaaga 257 cctcag
12 GTGGTGGCAC 135 ATGAGGCGGG (1358) gtcagt 580 ccacag
13 GGTAATCCTG 109 GTTCAAACAG (1467) gtaccc 1258 ttgcag
14 ATCCGCCTCA 85 CAGATCCAGT (1552) gtgagt 2076 cctcag
15 ACCACAGCAC 101d (GGACCAGAAG) (1653)
aNumbers in parentheses indicate cDNA positions [3].
bAccording to [10].
cThe coding part of exon 1 contains 209 bp.
dThe coding part of exon 15 contains 101 bp.
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cDNA. This analysis revealed homozygosity for the 833TCC
mutation (I278T) [12]. However, ampli¢cation of exon 8 and
mutation-speci¢c restriction enzyme analysis of genomic
DNA [13] showed that both patients were heterozygous for
the mutation (data not shown), indicating that the sequencing
analysis using the conventional method comprised only one
allele. cDNA being synthesised from only one allele can be
due to lacking transcription or an unstable transcript from the
second allele, or preferential PCR ampli¢cation of one allele,
most likely due to low levels of mRNA transcribed from the
second allele and subsequent competition between the alleles
during PCR. To determine a presumed second disease-causing
mutation on the allele not seen in the obtained cDNA se-
quence, we analysed genomic DNA comprising the entire cod-
ing region of the CBS gene as described above. The sequenc-
ing analysis revealed a novel 22 bp deletion of exon 4 (493^
514del), resulting in the introduction of a stop codon imme-
diately after the deletion. Gel electrophoretic analysis of the
PCR products prior to sequencing also showed that PCR
products of exon 4 from both patients consisted of two bands
of di¡erent mobility (Fig. 1). Furthermore, genomic DNA
sequencing analysis showed that the patients were heterozyg-
ous for the 833TCC mutation in exon 8 in accordance with
the restriction enzyme analysis, and both were heterozygous
for the 699CCT polymorphism (Y233Y) and heterozygous
for the 1080TCC polymorphism (A360A) [3]. The cDNA
sequence, however, showed that both patients were homozy-
gous for the 699CCT polymorphism and the 1080TCC
polymorphism which further con¢rms the absence of one al-
lele in the cDNA pool.
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Table 2
CBS intron sequences
Intron 5P Intron sequence (50 bp listed) 5P to 3P 3P Intron sequence (50 bp listed) 5P to 3P
1 gtaagtcctgcttttgatcacaagagggctgatccataacctg-
gagggca
tttcctgaataattgtggactcctctgtttcag
2 gtgagtgccctggctttggagaggggcttcctccatcta-
cactgggctcc
tgggggggtggtcagggggtcccctcctgtgattcatctctgcctcccag
3 gtgggtgccaggcccagaggggtggccggggctggctgtcccc-
tacccat
gcagggcttggggggtcactgggcccctctcaccctctgtgtgccctcag
4 gtgggtgggcgtggccaggggcggggtcatagggcaggggatga-
gggtgca
ctgggccaggcggaaggtgcaggccaccgctttccctcctgcaga
5 gtgaggcacctggggcctggagacaggcattccctaggagggt-
ctcggtcagga
gatgtgggggtgactgaggtgtcaggggtcagctcacgggctctgctctc-
tttctatgcaga
6 gtgcgtccctctgtccatcttgattgcatt cagggacccaagaagttatccgtccaccag
7 gtgagtggtgtggccgggccggagaggggc ctggccttgagccctgaagccgcgccctctgcag
8 gtaggtcgagtccagagcccggccacagtgccggtgcagcctg-
taactcaccc
cgtgggagcggctcccacgctgacgggctgtggtggggtcctgctcag
9 gtgagtgggtggcgggcacgggggtatggg ggcgcgtctgactcgtggccctctctgcag
10 gtaagacacggcttccctcccaggtccctgctcctctc-
catcctgccacc
cgggggcccggtggggcctgcggggactcggtgactcccccatcccgcag
11 gtaagaccgctcggccggagacccgctgcctgtgctggccctg-
cccagtg
cgagagcgtttgtccttatcctgaccccccgacctgccctcttccctcag
12 gtcagtctcagcccctgctcagagct-
cagtcctgggttctgtctgcccagctcc
tgggaggggtgaggtatgagcgctgacccctgcctgcccccgtcccacag
13 gtacccagtcacctacaggcagctcaaacagatgcgcagtcacc-
tacagg
aaactcgtggggccatgttccccctgccactgaccacgcttcccttgcag
14 gtgagtggggccctgctctgtgcgtggggttctcactggggt-
caggccac
acccagcctcccacggcacctgcaaacccactgcctcgttctcccctcag
3PUTR agtccggagcgctgggcggtgtggagcgggcccgccacccttg-
cccactt
aThe entire intron sequence is listed.
Table 3
Primers used for ampli¢cation of exon 1^15 of the CBS genea
Exon Sense primer (5PC3P) Antisense primer (5PC3P) Annealing temperature (‡C)
1 GGAACCCCACAGCATCCGAG TCAGCCCTCTTGTGATCAAAAGC 62
2 TTCCTGAATAATTGTGGACTCC GAAGCCCCTCTCCAAAGCC 58
3 GGGTGAGCAGGAATCAATGGG CTGGCCACCCCTCTGGGC 62
4 GGGCCCCTCTCACCCTCTG TGACCCCGCCCCTGGCCAC 64
5 GGTGCAGGCCACCGCTTTCCC GGAATGCCTGTCTCCAGGCCCC 64
6 GCTCACGGGCTCTGCTCTC ACGCAATCAAGATGGACAGAGG 64
7 CATTTACCCAAGAAGTTATCCGTCC CCTCTCCGGCCCGGCCACAC 58
8 CTTGAGCCCTGAAGCCGCGCC GTGGCCGGGCTCTGGACTCG 64
9 CTGTGGTGGGGTCCTGCT CCGTGCCCGCCACCCAC 64
10 GCGCGTCTGACTCGTGGCCC GCAGGATGGAGAGGAGCAGGG 64
11 CGGGGACTCGGTGACTCCC CAGCGGGTCTCCGGCCGAG 62
12 CCCCCGACCTGCCCTCTTCC CTGAGCTCTGAGCAGGGGCTG 64
13 GTGCTGACCCCTGCCTGCCC CTGCCTGTAGGTGACTGGGTACb 68
14 CATGTTCCCCCTGCCACTGAC CGCAGGGGATGGGGGGCC 64
15 CCCATGGTGCACAGGTGCC CACACCGCCCAGCGCTCCG 64
aTo the listed primers, an M13 sequence was added 5P to the gene-speci¢c sequence. These are: M13-21: TGTAAAACGACGGCCAGT (sense
primer) and M13 rev: CAGGAAACAGCTATGACC (antisense primer).
bThis primer was designed to span the intron boundary because a large number of repetitive sequences is present in intron 13.
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The asymptomatic sister and the mother of the patients
were subsequently investigated. Both displayed normal total
homocysteine in plasma (tHcy), 9.1 and 8.0 WM respectively.
Sequence analysis of genomic DNA showed a normal geno-
type in the sister (Fig. 1). The polymorphic 699CCT substi-
tution was not present, whereas she was homozygous for the
polymorphic 1080TCC substitution. The mother was hetero-
zygous for the 833TCC mutation, heterozygous for the
699CCT polymorphism and homozygous for the
1080TCC polymorphism. No samples were available for
analysis of the genotype of the father who died several years
ago from myocardial infarction at the age of 58 years. The
results of the genetic analysis indicate that the 22 bp deletion
of exon 4 present in the patients was the paternal CBS allele.
By combining the sequences of cDNA and genomic DNA, we
could determine the haplotype of the investigated alleles. The
haplotype of the maternal disease-causing allele was deter-
mined to be: 699T, 833C and 1080C, and the haplotype of
the paternal allele, presumably carrying the 22 bp deletion,
was: 699C, 833T and 1080T. The two normal alleles of the
sister both had the haplotype: 699C, 833T and 1080C.
3.4. Measurement of CBS activity in ¢broblasts
CBS enzyme activity was measured in extracts of cultured
¢broblasts. Without addition of PLP, activities were 0.46 and
0.66 nmol cystathionine/mg protein/h, respectively (normal
activity range: 2.3^18.2). In the presence of 1 mM PLP, the
activity was 0.92 and 1.04, respectively (normal activity range:
3.5^22.3). Addition of AdoMet even lowered the activity to
0.16 and 0.55, whereas in controls the activity is increased
three-fold. On admission, tHcy was 295 WM and 257 WM,
respectively. Folic acid therapy using 5 mg daily for 2 weeks
did not change the level of tHcy, whereas pyridoxine therapy
using 250 mg/day in combination with 5 mg folic acid for 6
additional weeks resulted in lowering of tHcy to 80 WM and
37 WM, respectively. Although reduced, tHcy levels after pyr-
idoxine treatment were still within the range of intermediate
hyperhomocysteinemia (30 WM6 tHcy6 100 WM) [11], and
the patients were considered partly pyridoxine-responsive.
Treatment with betaine is planned but results are not available
at the present time.
4. Discussion
Determinations of the genetic defects that cause homocys-
tinuria due to CBS de¢ciency have revealed a wide hetero-
geneity of disease-causing mutations. Because of the hetero-
geneity of mutations in CBS de¢ciency, detection of the
molecular defects that cause CBS de¢ciency requires appro-
priate screening methods including the entire coding region of
the gene. This analysis is essential for improved understanding
of the molecular mechanisms involved in CBS de¢ciency, and
for further studies of genotype-phenotype relationships. In
addition, detection of disease-causing, in several cases private,
mutations can provide useful information for the treatment of
CBS-de¢cient patients, which includes treatment with one or
several of the homocysteine-lowering agents pyridoxine, be-
taine and folic acid [14].
To obtain an improved and facilitated method for mutation
analysis, we elucidated the intron-exon boundaries of the CBS
gene. This has enabled the design of speci¢c primers that are
each located in an intron, immediately 5P or 3P to the exon in
question. This enabled the detection of mutations within the
entire coding region of the CBS gene, including the intron-
exon boundaries. We compared the established method with
the conventional method to detect the disease-causing muta-
tions in two Danish siblings with severe hyperhomocysteine-
mia. Genetic analysis using direct sequencing of cDNA indi-
cated homozygosity for the 833TCC mutation. Subsequent
analysis of genomic DNA by PCR ampli¢cation of exon 8
and mutation-speci¢c restriction enzyme analysis revealed het-
erozygosity for the mutation, indicating that only one allele
had been expressed and sequenced. Using the method de-
scribed in this study, heterozygosity for the 833TCC muta-
tion was con¢rmed. Furthermore, on the second allele we
detected a novel 22 bp deletion in exon 4 (493^514del), fol-
lowed immediately by an introduced nonsense codon. The
mother of the patients was heterozygous for the 833TCC
mutation, whereas the sister had none of the mutations. Pre-
sumably, the deleted allele was inherited from the father. The
deletion, resulting in a stop codon, in exon 4 obviously makes
the allele undetectable by the conventional method. Generally,
the closer a nonsense codon resides relative to the initiation
codon, the more likely the nonsense codon will reduce mRNA
abundance [15]. Likely, the mRNA from the deleted allele is
unstable and degraded rapidly.
Our patients were considered partly pyridoxine-responsive
according to Wilcken et al. [16]. In addition, the ¢broblast
enzyme activity of the patients was low, but not zero, and
no stimulation with AdoMet was obtained. This is in accord-
ance with results of Kluijtmans et al. [17] who also detected
CBS activity in the heterozygous range and no stimulation
with AdoMet in a CBS-de¢cient patient. Often, no ¢broblast
residual activity is present in pyridoxine non-responsive pa-
tients, whereas pyridoxine-responsive patients often have
some residual activity [18]. Con£icting data on the pyridoxine
responsiveness of the 833TCC mutation have been presented.
Hu et al. [19] reported that the 833TCC mutation usually
confers pyridoxine responsiveness, whereas results from a
yeast functional assay indicated pyridoxine non-responsive-
ness [20]. This may be due to di¡erent folding and processing
mechanisms in yeast. It has been observed that di¡erent com-
binations of allelic variants can result in a modi¢cation of the
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Fig. 1. Genotypes of investigated family members. Upper panel
shows the pedigree of the family. 3: patient 1; 4: patient 2; 5: sis-
ter; 6: mother; ¢lled ¢gure: 833TCC mutation; hatched ¢gure: 22
bp deletion. Lower panel shows the con¢rmation of the presence of
the 22 bp deletion by gel electrophoretic analysis of PCR products
of exon 4. Lane 1: DNA size marker; lane 2: control; lane 3: pa-
tient 1; lane 4: patient 2; lane 5: sister; lane 6: mother; lane 7:
DNA size marker.
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phenotype conferred by one variant when combined with a
second allelic variant [5].
We determined the haplotypes of the normal and the patho-
genic alleles to deduce whether the 699CCT or the
1080TCC polymorphism was linked to the 833TCC muta-
tion. In this family the 833T allele was always associated with
the 699C variant, whereas the 833C allele co-segregated with
the 699T variant. The 1080T variant was only present on the
allele containing the 22 bp deletion. Furthermore, the haplo-
type analysis con¢rmed the lack of cDNA sequence from the
allele with the deletion.
Taken together, our established method has several advan-
tages compared to the existing methods based on analysis of
cDNA from ¢broblasts or lymphocytes. The analysis of ge-
nomic DNA can be performed using a small amount of pe-
ripheral blood (300 Wl) as sample material. Furthermore, the
use of intronic primers permits the detection of splice muta-
tions, of which only one has previously been reported among
CBS-de¢cient patients [5]. It is well known that many genetic
diseases are attributable to mutations that result in splicing
defects [21]. Consequently, further analysis of genomic DNA
from CBS-de¢cient patients in whom only one allele was seen
in the cDNA sequencing, as reported [22], may reveal the
presence of a splicing defect on the other allele. Alternatively,
mutations resulting in a null allele or an unstable and rapidly
degraded mRNA could be present. Relatively few splice mu-
tations and deletions have been detected among CBS-de¢cient
patients. This may be due to the lack of appropriate screening
methods until now. Automated sequencing is made possible
by the use of the Catalyst Molecular Biology LabStation and
by using only two di¡erent sequencing primers for all exons.
This is time-saving and facilitates the sequencing procedure.
In addition, the presence of frequently occurring CBS muta-
tions can now be investigated in a large number of patients in
routine analysis for detection of heterozygotes or homozy-
gotes for CBS de¢ciency. The designed intronic primers re-
ported here can be applied to other screening methods as well,
such as single-strand conformation polymorphism analysis.
The ampli¢ed PCR products are small (160^300 bp) and
thus well suited for this kind of mutation analysis.
The present method permits a facilitated and improved de-
tection of heterozygotes for CBS de¢ciency. To date, determi-
nation of carrier state has been performed by measurement of
¢broblast CBS activity or methionine loading tests [23]. Now,
we can perform the analysis using a peripheral blood sample.
The facilitated detection of heterozygotes for CBS de¢ciency
may be valuable in the further elucidation of a possible im-
plication of heterozygosity for CBS de¢ciency in occlusive
peripheral and cerebral arterial disease [24]. Especially, the
characterisation of obligate heterozygotes is facilitated:
when the pathogenic mutations have been detected in a pa-
tient with CBS de¢ciency, it is su⁄cient to analyse for the
presence of these mutations in the parents to determine
whether they are carriers of one of those mutations, or
whether the detected mutations are de novo mutations.
In conclusion, by elucidating the intron-exon boundaries of
the 15 coding CBS exons we have established a novel screen-
ing method based on genomic DNA for mutation analysis in
the CBS gene. Using this method, we have identi¢ed a novel
22 bp deletion of exon 4, which was undetectable by sequenc-
ing of cDNA. Thus, our method is preferable to the existing
screening methods because a minute amount of sample is
used, and the sensitivity is higher than that of the conven-
tional method because the detection of splice mutations and
mutations resulting in no or a low amount of transcript is
enabled.
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